AIMS/HYPOTHESIS: Glucagon-like peptide-1 (GLP-1), secreted by the enteroendocrine L cell, is an incretin hormone that potently stimulates insulin secretion. Although signalling pathways promoting GLP-1 release are well characterised, the mechanisms by which GLP-1-containing granules fuse to the L cell membrane are unknown. As soluble NSF attachment proteins (SNAREs) are known to mediate granule-membrane fusion, the role of vesicle-associated membrane proteins (VAMPs) in GLP-1 exocytosis was examined. METHODS: SNARE expression was determined in murine GLUTag L cells by RT-PCR and immunoblot and in primary murine L cells by immunofluorescence. Co-immunoprecipitation was used to examine SNARE interactions, while tetanus toxin (TetX)-mediated cleavage of VAMP was used with a GLP-1 secretion assay and total internal reflection fluorescence microscopy to determine the role of VAMP2 in exocytosis. RESULTS: VAMP2 was expressed in murine L cells and localised to secretory granules in GLUTag cells. VAMP1/3 and the core membrane proteins syntaxin1a and synaptosomal-associated protein 25 kDa (SNAP25) were also detected. TetX cleaved VAMPs in GLUTag cells. However, only VAMP2 interacted with syntaxin1a, as did SNAP25 and Munc18-1. TetX treatment of GLUTag cells prevented glucose-dependent insulinotrophic peptide- and oleic-acid-stimulated GLP-1 secretion (p < 0.05-0.01), as well as K(+)-stimulated single-cell exocytosis (p < 0.05-0.001), while TetX-resistant VAMP2 expression rescued GLP-1 secretion (p < 0.01-0.001). CONCLUSIONS/ INTERPRETATION: Together, these findings indicate an essential role for VAMP2 in GLP-1 exocytosis from the GLUTag L cell in response to a variety of established secretagogues. An improved understanding of the mechanisms governing the release of GLP-1 may lead to new therapeutic approaches to enhance the levels of this incretin hormone in patients with type 2 diabetes.
AIMS/HYPOTHESIS: Glucagon-like peptide-1 (GLP-1), secreted by the enteroendocrine L cell, is an incretin hormone that potently stimulates insulin secretion. Although signalling pathways promoting GLP-1 release are well characterised, the mechanisms by which GLP-1-containing granules fuse to the L cell membrane are unknown. As soluble NSF attachment proteins (SNAREs) are known to mediate granule-membrane fusion, the role of vesicle-associated membrane proteins (VAMPs) in GLP-1 exocytosis was examined. METHODS:SNARE expression was determined in murine GLUTag L cells by RT-PCR and immunoblot and in primary murine L cells by immunofluorescence. Co-immunoprecipitation was used to examine SNARE interactions, while tetanus toxin (TetX)-mediated cleavage of VAMP was used with a GLP-1 secretion assay and total internal reflection fluorescence microscopy to determine the role of VAMP2 in exocytosis. RESULTS:VAMP2 was expressed in murine L cells and localised to secretory granules in GLUTag cells. VAMP1/3 and the core membrane proteins syntaxin1a and synaptosomal-associated protein 25 kDa (SNAP25) were also detected. TetX cleaved VAMPs in GLUTag cells. However, only VAMP2 interacted with syntaxin1a, as did SNAP25 and Munc18-1. TetX treatment of GLUTag cells prevented glucose-dependent insulinotrophic peptide- and oleic-acid-stimulated GLP-1 secretion (p < 0.05-0.01), as well as K(+)-stimulated single-cell exocytosis (p < 0.05-0.001), while TetX-resistant VAMP2 expression rescued GLP-1 secretion (p < 0.01-0.001). CONCLUSIONS/ INTERPRETATION: Together, these findings indicate an essential role for VAMP2 in GLP-1 exocytosis from the GLUTag L cell in response to a variety of established secretagogues. An improved understanding of the mechanisms governing the release of GLP-1 may lead to new therapeutic approaches to enhance the levels of this incretin hormone in patients with type 2 diabetes.
Authors: Natalia Gustavsson; Shun-Hui Wei; Dong Nhut Hoang; Ye Lao; Quan Zhang; George K Radda; Patrik Rorsman; Thomas C Südhof; Weiping Han Journal: J Physiol Date: 2009-01-26 Impact factor: 5.182
Authors: Natalia Gustavsson; Ye Lao; Anton Maximov; Jen-Chieh Chuang; Elena Kostromina; Joyce J Repa; Cai Li; George K Radda; Thomas C Südhof; Weiping Han Journal: Proc Natl Acad Sci U S A Date: 2008-02-28 Impact factor: 11.205
Authors: Patrick P L Lam; Mitsuyo Ohno; Subhankar Dolai; Yu He; Tairan Qin; Tao Liang; Dan Zhu; Youhou Kang; Yunfeng Liu; Maria Kauppi; Li Xie; Wilson C Y Wan; Na-Rhum Bin; Shuzo Sugita; Vesa M Olkkonen; Noriko Takahashi; Haruo Kasai; Herbert Y Gaisano Journal: Diabetes Date: 2013-02-19 Impact factor: 9.461
Authors: Sarah E Wheeler; Holly M Stacey; Yasaman Nahaei; Stephen J Hale; Alexandre B Hardy; Frank Reimann; Fiona M Gribble; Pierre Larraufie; Herbert Y Gaisano; Patricia L Brubaker Journal: Diabetes Date: 2017-06-08 Impact factor: 9.461
Authors: Andrew D Biancolin; Alexandre Martchenko; Emilia Mitova; Patrick Gurges; Everan Michalchyshyn; Jennifer A Chalmers; Alessandro Doria; Josyf C Mychaleckyj; Alice E Adriaenssens; Frank Reimann; Fiona M Gribble; Manuel Gil-Lozano; Brian J Cox; Patricia L Brubaker Journal: Mol Metab Date: 2019-11-21 Impact factor: 7.422
Authors: Alexandre Martchenko; Sarah E Martchenko; Andrew D Biancolin; Patricia L Brubaker Journal: Endocrinology Date: 2020-12-01 Impact factor: 4.736
Authors: Luis F Sifuentes-Dominguez; Haiying Li; Ernesto Llano; Zhe Liu; Amika Singla; Ashish S Patel; Mahesh Kathania; Areen Khoury; Nicholas Norris; Jonathan J Rios; Petro Starokadomskyy; Jason Y Park; Purva Gopal; Qi Liu; Shuai Tan; Lillienne Chan; Theodora Ross; Steven Harrison; K Venuprasad; Linda A Baker; Da Jia; Ezra Burstein Journal: Elife Date: 2019-10-30 Impact factor: 8.713
Authors: Jhenielle R Campbell; Alexandre Martchenko; Maegan E Sweeney; Michael F Maalouf; Arianna Psichas; Fiona M Gribble; Frank Reimann; Patricia L Brubaker Journal: Endocrinology Date: 2020-05-01 Impact factor: 4.736